Home › Companies › NAMS

Pipeline (6 active programs)

Capital (as filed)

Cash

$423M cash and cash equivalents · Sep 30, 2026 (10-Q)

Short-term investments

$205M Sep 30, 2026

Long-term investments

$14.9M Sep 30, 2026

Operating cash flow

−$39.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$643M cash per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

• 2026-11-05 UPDATE: NewAmsterdam Pharma (NAMS) - The Last Checkpoint Before the Coin Flip 🔒 Paid
• 2026-09-22 UPDATE: NewAmsterdam Pharma (NAMS) - Approved in Europe, Still Unfiled in America 🔒 Paid
• 2026-08-06 UPDATE: NewAmsterdam Pharma (NAMS) - The NDA That Still Isn’t There 🔒 Paid
• 2026-08-04 NewAmsterdam Pharma (NAMS) — Scientific Deep Dive for Obicetrapib and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on NewAmsterdam Pharma, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-08-04 Watch NewAmsterdam Pharma (NAMS) — Scientific Deep Dive for Obicetrapib and Pipeline Products The mechanism, tolerability data, balance sheet, and European approval are real, but a single Q1 2027 DSMB recommendation determines whether this is a cardiovascular franchise or a European specialty product, and with no U.S. NDA on file against a newly approved oral PCSK9 inhibitor, the unresolved question is too large to act on before that date.
2. 2026-08-06 Watch UPDATE: NewAmsterdam Pharma (NAMS) - The NDA That Still Isn't There Q2 confirmed the thesis without advancing it — balance sheet held, Alzheimer's biomarker signal improved, Europe nearing procedural approval — but no U.S. NDA date was provided and the single binary DSMB recommendation in Q1 2027 remains the only thing that matters.
3. 2026-09-22 Watch UPDATE: NewAmsterdam Pharma (NAMS) - Approved in Europe, Still Unfiled in America EC approval of Ubeslo and Evlarco converts a modeled cash flow into a contracted one, but the EC also attached PREVAIL final results as a post-authorization efficacy obligation, making the Q1 2027 DSMB recommendation matter on both sides of the Atlantic with no U.S. NDA still on file.
4. 2026-11-05 Watch UPDATE: NewAmsterdam Pharma (NAMS) - The Last Checkpoint Before the Coin Flip Q3 cash held at $643.1M with ATM undrawn, but the UK launch slipped to 2027, a new MFN pricing risk disclosure suggests European prices could cap U.S. upside, and the PREVAIL DSMB recommendation remains the sole binary with no U.S. NDA date in sight.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

• 2026-08-05 10-Q in filings ↓

  • “We expect to receive the DSMB’s recommendation based on the interim analysis in the first quarter of 2027.”

    matched to PREVAIL (obicetrapib) · interim data · read as first quarter of 2027 / matched to PREVAIL (obicetrapib) · readout other · read as first quarter of 2027
• 2026-08-05 10-Q in filings ↓

  • “We expect to receive the DSMB’s recommendation based on the interim analysis in the first quarter of 2027.”

    matched to PREVAIL (obicetrapib) · readout other · read as first quarter of 2027

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Nov 4, 2026ReleaseNewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results→ BD updateSummary on the 8-K
• Nov 4, 20268-KCurrent report · EX-99.1→ BD updateWith the PREVAIL interim event count on track for Q4 2026 and a DSMB recommendation landing in Q1 2027, the binary I've been tracking is now weeks away — and today's Q3 update confirms $643.1M in cash, a new Phase 2b Alzheimer's trial (SPINOZA), and a RUBENS readout before year-end.
• Nov 4, 202610-QQuarterly report→ BD updateSummary on the 8-K
• Nov 3, 2026ReleaseNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
• Sep 29, 2026ReleaseNewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s DiseaseSummary on the 8-K
• Sep 29, 20268-KCurrent report: other events · EX-99.1NAMS dosed the first participant in SPINOZA today — a randomized, double-blind, placebo-controlled Phase 2b trial of obicetrapib in ~400 preclinical Alzheimer's patients — converting the Alzheimer's program from a biomarker sub-study into an actual controlled trial, though the thesis remains anchored to PREVAIL's Q1 2027 DSMB readout.
• Sep 22, 2026SCHEDULE 13D/A13D amendment
• Sep 21, 2026ReleaseNewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)→ BD updateSummary on the 8-K
• Sep 21, 20268-KCurrent report: other events→ BD updateEurope just said yes — the EC granted full marketing authorization for Ubeslo® and Evlarco® today, the first regulatory approval of obicetrapib anywhere in the world, triggering milestone payments and opening the royalty clock. The stock is down ~18% since August. Here's why the market isn't celebrating, and what the EC's PREVAIL condition actually means for the thesis.
• Sep 2, 2026ReleaseNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
• Aug 26, 2026ReleaseNewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
• Aug 14, 20268-K/ACurrent report (amended): officer / director change
• Aug 14, 20268-KCurrent report: officer / director change
• Aug 5, 2026ReleaseNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial ResultsBD extracted 2 program updates from this document → NAMS pipeline
• Aug 5, 20268-KCurrent report: results of operations · EX-99.1
• Aug 5, 202610-QQuarterly report
• Jul 24, 20268-KCurrent report: other events · EX-99.1
• Jul 22, 20268-KCurrent report: officer / director change
• Jun 3, 20268-KCurrent report: officer / director change, shareholder vote
• May 14, 2026SCHEDULE 13D/A13D amendment
• May 7, 20268-KCurrent report: results of operations · EX-99.1
• May 7, 202610-QQuarterly report
• May 6, 2026DEF 14AProxy statement
• Apr 24, 20268-KCurrent report: officer / director change
• Mar 2, 20268-KCurrent report: Reg FD disclosure · EX-99.1